Alzheimer ' s disease (AD) is characterized by abnormal senile plaque and neurofi brillary tangle formation. Derived from the amyloid-␤ (A ␤ ) precursor protein (A ␤ PP), A ␤ peptide is the major component of senile plaques in the brain and cerebrovasculature. A ␤ is thought to be a major contributor to the neurodegenerative process, acting either through neurotoxic mechanisms or local infl ammatory processes ( 1 ) . However, Alzheimer ' s pathology is not limited to neurons, as one of the earlier manifestations of the disease is abnormal cerebral vasculature. This neurovascular pathology may accelerate other A ␤ -mediated pathologies or aff ect neuronal damage directly ( 2 -4 ) .
Fibrinogen is a 340-kD macromolecule classically known for its role as the protein component of blood clots and is normally excluded from the brain parenchyma by the blood -brain barrier. Neurovascular damage can allow fibrinogen access to the central nervous system. Fibrinogen is present in the brains of AD patients ( 5 ) , but the pathologic signifi cance is not known.
Fibrin deposition increases in the context of defi ciency in the tissue plasminogen activator/ plasminogen (tPA/plg) protease cascade ( 6 ) . Plasminogen-defi cient mice accumulate extravascular fi brin and have impaired wound healing and high mortality, both of which are corrected in mice defi cient for both plasminogen and fi brinogen ( 7 ) . Fibrin accumulation can also be reduced genetically or pharmacologically with administration of the fi brinogen-depleting protease ancrod. This serine protease derived from the venom of the Malayan pit viper Agkistrodon rhodostoma has been used to alleviate fi brinmediated pathology in various systems ( 8, 9 ) .
In the brains of AD patients and mouse models of the disease, clearance of fi brin by the tPA/plasmin system is expected to be reduced as tPA activity is diminished ( 10, 11 ) . Because infl ammation is universal in A ␤ PP transgenic mice and can be observed as early as 13 wk of age ( 12 ) , we hypothesized that extravasated fi brin might initiate or exacerbate the observed neuroinfl ammation. We further hypothesized that this exaggerated fi brin-induced infl ammatory process could infl ate the damage to the vasculature, thus promoting this process of disease progression.
Because Evans blue dye binds to albumin in the blood, extravasation of the dye serves as a marker for blood -brain barrier permeability and neurovascular damage. We compared Alzheimer ' s mouse models Tg2576, PDAPP, and TgCRND8 to nontransgenic littermates for defects in the neurovasculature. Because these mice bear A ␤ PP with diff erent familial AD mutations and are driven by diff erent promoters, they exhibit diff ering ages of onset of A ␤ -associated pathology. Therefore, we compared extravasation of Evans blue dye in mice at 6 and 12 mo of age.
As shown in Fig. 1 A , brains of all three Alzheimer ' s mouse models were considerably more permeable to the dye. Nontransgenic littermates showed increased bloodbrain barrier permeability as age increased. However, in all three Alzheimer ' s mouse models, the brain was considerably more permeable to the dye at these ages. These data are consistent with previously observed microvascular damage in the We sought to examine these possibilities by measuring blood -brain barrier permeability and fi brin deposition in three mouse models of AD. Our results demonstrate blood -brain barrier damage and the presence of fi brin in the parenchyma in AD mice. Modulation of fi brinogen levels aff ects the pathology of AD mice: reducing fi brinolysis, thereby increasing fi brin deposition, worsens the pathology, whereas fi brinogen depletion attenuates microgliosis and neurovascular damage. These results indicate a role for fi brin in aggravating and accelerating the infl ammatory component of disease progression in transgenic A ␤ PP-overexpressing mice.
RESULTS
Fibrin is deposited through a disrupted neurovasculature in transgenic mouse models of AD When the blood -brain barrier is compromised, macromolecules in circulation can accumulate in the brain parenchyma ( 13 ) . Blood -brain barrier permeability and neurovascular damage is increased in three mouse models of AD. (A) Evans blue assay indicates increased blood -brain barrier permeability in the Tg2576, PDAPP, and TgCRND8 transgenic mice compared with nontransgenic (NTg) littermates. Data are given as Evans blue extravasation calculated from A 620 of perfused brain homogenates and normalized to plasma Evans blue levels. For 6-mo mice, n ϭ 9 for NTg (three each from Tg2576, PDAPP, and TgCRND8 litters), n ϭ 3 for Tg2576, n ϭ 6 for PDAPP, and n ϭ 7 for TgCRND8; for 12-mo mice, n ϭ 9 for NTg (three each from Tg2576, PDAPP, and TgCRND8 litters), n ϭ 4 for Tg2576, n ϭ 4 for PDAPP, and n ϭ 4 for TgCRND8. Error bars represent the mean Ϯ SEM. *, P Ͻ 0.05; **, P Ͻ 0.001, relative to nontransgenic littermates. (B) Laser-scanning micrograph of microvasculature in hippocampus of 6-mo TgCRND8 mouse and NTg littermate injected with Evans blue (red) 6 h before and perfused at the time of killing with 2,000-kD dextran (green). Fluorescence intensity across a cross section (indicated by white arrow; 100 m) of a capillary is scanned for the distribution of each fl uorochrome.
circulation by ancrod. Accordingly, sections of perfused brains after ancrod treatment showed diminished fi brin immunoreactivity (see Fig. 7 A ) .
Perfused sections of transgenic brains from each treatment group were stained with CD11b, an integrin receptor present on microglia, and infl ammatory foci were visualized. The total area of infl ammatory foci can be quantifi ed within the regions of interest, as shown in Fig. 3 A . Areas of infl ammation were compared between ancrod and saline. Ancrod treatment reduced the area of infl ammation by ‫ف‬ 64% ( Fig. 3 C ; P = 0.00001). In saline-treated mice, microglia were identifi ed by their amoeboid morphology. As shown in Fig. 3 D , these aggregated microglia formed infl ammatory foci and appeared to concentrate around plaques with reduced number after fibrinogen depletion. Because ancrod is a protease and could be acting directly on A ␤ levels, we quantifi ed levels of plasma A ␤ 1-40 and cortical A ␤ , neither of which were substantially diff erent in ancrod-treated mice ( Fig. 3 B ) , indicating that depletion of fi brinogen, rather than deposited A ␤ , is responsible for the reduced microgliosis.
As infl ammation can contribute to blood -brain barrier permeability, we assayed ancrod-treated mice for Evans blue extravasation and found a reduction when compared with saline-treated mice (see Fig. 7 B ) . This attenuation of vascular damage prompted analysis of the microvasculature from both cortex and hippocampus. Identical areas of the brain ( Fig.  4 A ) were quantifi ed for vascular density as a percentage of image area ( Fig. 4 B ) and indicated that ancrod treatment partially prevents blood vessel loss.
Tg2576 mouse ( 14 ) , although the TgCRND8 mice show earlier onset.
To visually observe extravascular deposition of Evans blue, mice treated with Evans blue for 6 h were perfused with fl uorescent dextran at the time of killing. This 2,000-kD dextran is impermeable to both healthy and damaged blood vessels, and therefore serves as an outline of intravascular space. The nontransgenic littermate blood -brain barrier retained both dyes within the blood vessel as shown in Fig. 1 B  (left) . The damaged TgCRND8 blood vessel in Fig. 1 B  (right) showed diff use accumulation of Evans blue around the contained dextran. As shown underneath each micrograph, the distribution of each fl uorochrome can be analyzed for fl uorescence intensity across a cross section of a capillary, which reveals Evans blue with a broader distribution than the dextran in the AD mouse ( 15 ) . Together with the quantitative extravasation assay, these comprehensive estimates indicated increased blood -brain barrier permeability in the TgCRND8 mouse.
To gain insight into blood vessel health, mice brain sections were stained for platelet/endothelial cell adhesion molecule-1 (PECAM-1). Images of perfused and stained microvasculature were obtained from the cortex of TgCRND8 mice and nontransgenic littermates at 6 mo of age (Fig. S1 , available at http://www.jem.org/cgi/content/full/jem.20070304/ DC1). Healthy endothelial cells constitutively express this surface marker ( 16 ) , but sections of TgCRND8 brains showed diminished signal intensity, and vessels appeared tortuous and fragmented.
Because the AD mouse blood -brain barrier was permeable to albumin-bound Evans blue dye, we hypothesized that fi brinogen could gain access to the brain ' s extravascular space. Given this, and because tPA activity is reduced in the AD mouse brain ( 11 ), we reasoned that fi brin could deposit and accumulate over the lifespan of the mouse. Perfused TgCRND8 brains contained elevated levels of fi brin as determined by ELISA. 3 -9-mo-old mice showed that A ␤ accumulated in an age-dependent manner, and fi brin levels correlated with soluble A ␤ 1-40 and A ␤ 1-42 levels, as measured by ELISA from the same tissue homogenates ( Fig. 2 ) .
Neuroinfl ammation and microvascular injury are diminished by pharmacologic depletion of fi brinogen
Because fi brin is a proinfl ammatory molecule and could aggravate pathology upon exiting the vasculature ( 17, 18 ), we asked if fi brinogen depletion might reduce the infl ammation in A ␤ PP transgenic mice. TgCRND8 mice are appropriate because of the early onset of neurovascular dysfunction and neuroinfl ammation, as seen by microgliosis at 13 wk ( 12 ). We therefore reduced circulating fi brinogen levels using a recombinant form of the Malayan pit viper protease ancrod. Ancrod is a thrombin-like protease that cleaves fi brin and prevents its polymerization, allowing degradation by the liver and removal from circulation ( 19, 20 ) . TgCRND8 mice were treated with either ancrod or saline for 4 wk before killing at 6 mo of age. Fibrinogen levels were reduced by 50 -75% in 
Neurovascular pathology in the transgenic mouse model is modulated by genetic defi ciency in plasminogen or fi brinogen
We crossed transgenic AD mice to mice defi cient for fi brinogen (fi b Ϫ/Ϫ ) to obtain TgCRND8;fi b +/Ϫ mice bearing only one copy of the fi brinogen gene. Additionally, because accumulated fi brin in the extravascular space can cause damage, we asked if a reduction in plasminogen levels on a background of the A ␤ PP transgene could promote neurovascular pathology. Similar to the fi brinogen cross, we generated TgCRND8;plg +/Ϫ mice and compared them to TgCRND8 littermates. We examined the N1 generation from mice crossed to TgCRND8 mice because pathology presents at an earlier age than PDAPP and Tg2576. Heterozygosity for plasminogen defi ciency in TgCRND8 mice produced a signifi cant increase in Evans blue extravasation ( Fig. 5 ; P = 0.042). Conversely, TgCRND8;fi b +/Ϫ mice showed reduced neurovascular pathology at 6 mo (P ϭ 0.003). Plg +/Ϫ and fi b +/Ϫ controls showed little permeability to the dye, suggesting that a product of the A ␤ PP transgene is necessary for neurovascular pathology. To control for the possible eff ects of diff erent genetic backgrounds on the production and metabolism of the A ␤ PP transgene, PDAPP mice were backcrossed Ͼ10 generations onto the C57BL/6 background before crossing with plg Ϫ/Ϫ mice, which share the C57 background. The results shown in To complement fi brinogen-depletion experiments, we tested whether absence of plasmin-mediated clearance of fi brin accelerates pathology. We treated TgCRND8 mice with a plasmin inhibitor, tranexamic acid, for 4 wk before killing at 6 mo of age alongside littermates treated with saline or ancrod. Infl ammatory foci were again visualized using microglia staining with CD11b ( Fig. 3 A ) . Plasmin inhibition by tranexamic acid treatment signifi cantly increased microgliosis in treated mice as compared with control mice (P ϭ 0.014; Fig. 3 C ) .
We also reasoned that the inhibition of plasmin-mediated clearance of fi brin and subsequent infl ammation could aggravate neurovascular damage in TgCRND8 mice. We observed that administration of tranexamic acid increases damage to the blood -brain barrier (see Fig. 7 ). Decreased blood -brain barrier integrity after 4-wk tranexamic acid treatment prompted analysis of the microvasculature. Tranexamic acid -treated TgCRND8 mice showed a reduction in microvascular density, and vessels appeared damaged ( Fig. 4 ) .
With the increased pathology observed in the tranexamic acid -treated animals, we asked if infl ammation and A ␤ were suffi cient to promote neurodegeneration. Active caspase-3 staining did not reveal apoptotic cells in treatment or control groups. Samples also were negative for neurodegeneration by Fluoro-Jade B staining (unpublished data). 
Fibrinogen depletion protects against the deleterious effects of plasmin inhibition
Suppressing plasmin activity with tranexamic acid leads to increased blood -brain barrier breakdown and infl ammation, as shown in Fig. 7 B and Fig. 3 C , respectively. As fi brin is the primary target of plasmin proteolysis, this treatment also led to increased fi brin deposition ( Fig. 7 A ) . However, because plasmin is a potent protease that could have many substrates, we investigated whether the vascular damage and infl ammation were due to fi brin accumulation or some other eff ect of plasmin inhibition. Therefore, we implanted pumps with either saline or ancrod in two groups of mice for a pretreatment period of 1 wk. After pretreatment, both fi brinogen-depleted and control groups received tranexamic acid, to inhibit plasmin activity for 1 wk. All mice were assayed for blood -brain barrier damage and infl ammation as before. As expected, plasmin inhibition increased Evans blue extravasation and microglial staining in the control group. By comparison, the fi brinogen-depleted group showed considerably less pathology ( Fig. 8 ) . Levels for fi brinogen-depleted mice were similar to those of untreated mice ( Fig. 1 A ) , suggesting that fi brinogen depletion protected mice from the increased vascular damage and infl ammation induced by plasmin inhibition. This result indicates that fi brin deposition is a critical pathologic consequence of reduced plasmin activity in the brains of AD mice.
DISCUSSION Neurovascular dysfunction in the A ␤ PP transgenic mouse
The Tg2576 mouse has defi cits in vascular integrity shown by blood -brain barrier damage ( 21, 22 ) , decreased blood fl ow, and increased susceptibility to ischemia ( 23 ) . In addition, vascular density is reduced in these animals, as measured by glucose transporter increased blood -brain barrier pathology in PDAPP;plg +/Ϫ mice when compared with PDAPP littermates, consistent with the results shown in Fig. 5 .
Because Evans blue dye is fl uorescent, the entire hemisphere can be visualized for dye extravasation to determine which areas of the brain are most aff ected. Images of cerebral hemispheres of each genotype were compared ( Fig. 6 ) . The cortex and hippocampus were aff ected with the highest levels of neurovascular damage, consistent with the observation that hippocampus and cortex show the most A ␤ deposition. The data indicated that the removal of one copy of the plasminogen gene accelerates the loss of microvascular integrity in TgCRND8 mice, whereas reduction of one copy of the fi brinogen gene slowed pathogenesis. At 3 mo of age, mice homozygous for plasminogen defi ciency showed blood -brain barrier damage (Fig. S3 , available at http:// www.jem.org/cgi/content/full/jem.20070304/DC1) but did not show substantial neuroinfl ammation. Because these mice died early, it cannot be determined if the infl ammation would have developed to levels comparable to those of older AD mice. Nonetheless, this fi nding indicates that the presence of A ␤ exaggerates fi brin-related neuroinfl ammation. . Genetic plasminogen and fi brinogen defi ciency modulate defects in the AD mouse blood -brain barrier. 6-mo-old AD mice deficient for plasminogen (TgCRND8;plg +/Ϫ ) and fi brinogen (TgCRND8;fi b +/Ϫ ) were assayed for Evans blue extravasation alongside TgCRND8 littermates. TgCRND8;plg +/Ϫ mice showed increased blood -brain barrier permeability, whereas TgCRND8;fi b +/Ϫ mice showed a decrease. Data are given as Evans blue extravasation calculated from A 620 of perfused brain homogenates and normalized to plasma Evans blue levels. n ϭ 8 for NTg; n ϭ 8 for TgCRND8; and n ϭ 3 for TgCRND8;plg +/Ϫ , TgCRND8;fi b +/Ϫ , fi b +/Ϫ , and plg +/Ϫ mice. Bars represent the mean Ϯ SEM. **, P Ͻ 0.001, relative to nontransgenics; † , P Ͻ 0.05, relative to TgCRND8.
The A ␤ peptide causes endothelial and smooth muscle cell dysfunction and cell death in vitro, thus disrupting two major components of the blood -brain barrier ( 25 -31 ). Therefore, the initial insult to the microvasculature likely arises from increased A ␤ levels. Cerebral amyloid angiopathy is a hallmark of AD, and it will be important to consider the specifi c vascular amyloid burden in these mice. type 1 beginning at 12 mo ( 24 ). Subsequently, it was shown that the blood -brain barrier compromise is rescued in the Tg2576 mouse with passive A ␤ 1-40 peptide immunization ( 14 ) . The present study explores the contribution of fi brin to neurovascular damage as part of the A ␤ disease process and broadens the knowledge of vascular defi cits to other A ␤ PP-transgenic mouse models. Additionally, plg Ϫ/Ϫ mice exhibit early mortality, which would preclude comparison at later ages. TgCRND8;fi b Ϫ/Ϫ mice are also diffi cult to generate because of breeding restrictions and limited survival ( 36 ).
These genetic constraints are addressed with the experiments using pharmacologic reduction of fi brinolysis and fibrinogen depletion by ancrod. The convergence of the results of both genetic and pharmacologic approaches forms solid evidence that manipulation of fi brin levels in Alzheimer ' s mouse models modulates infl ammation and vascular integrity.
Fibrinogen and infl ammation
Fibrinogen has several active roles in normal and abnormal physiology, including cellular responses in clotting and infl ammation that are mediated by fi brinogen receptors. Of interest in the present study are the integrin receptors expressed on leukocytes, monocytes, and macrophage/microglia. Three notable infl ammatory integrins are ␣ 5 ␤ 1 , ␣ v ␤ 3 , and ␣ M ␤ 2 (Mac-1 or CD11b/CD18; reference 37 ). Binding of the fi brinogen dimer to microglial ␣ M ␤ 2 /CD11b elicits activation of the NF-B pathway, causing increased expression of cytokine genes ( 38, 39 ) .
The involvement of infl ammation has been studied in AD. Clinical and epidemiological data concerning antiinfl ammatory medications are provocative and require further studies to determine their potential in controlling disease progression ( 40, 41 ) . The present study suggests that fi brin may be an upstream eff ector of neuroinfl ammation, and the damaging eff ect of decreased fi brinolysis on the neurovasculature is intriguing. Fibrin-induced microgliosis could be toxic to endothelial cells, as microglia have been shown to increase cell death in primary endothelial cells after oxygenglucose deprivation, which can be reduced by inhibiting microglial activation with minocycline ( 42 ) .
How infl ammation may contribute to neurodegeneration in AD is still largely unknown. As blood vessels from AD brains are directly toxic to neurons ( 43 ), we asked if the compromised neurovasculature and infl ammation in these experimental mice could promote neurodegeneration. Although we did not observe neuronal death, studies involving older TgCRND8 mice with enhanced infl ammation and vascular damage may reveal detectable levels of neurodegeneration.
As fi brinogen is polymerized after activation by thrombin, it is important to note that thrombin injection into the rat cortex induces microgliosis ( 44 ) . Additionally, in human patients with advanced AD, plasma prothrombin can be found in the extravascular space ( 45 ) , which provides an environment where fi brin is likely to deposit.
Once polymerized in the parenchyma, fi brin is covalently cross-linked by tissue-resident transglutaminase factor XIII ( 46 ) . Cross-linked fi brin is stabilized by covalent bonds between ␥ chains. Because the capturing antibody used in the ELISA recognizes the ␥ chain specifi cally ( 47 ) , some insoluble fibrin may have escaped detection, and the ELISA results likely underestimate the total fi brin deposition. However, the immunofl uorescence uses a polyclonal antibody, which detects However, the neurovascular damage in the plasminogendefi cient mouse suggests that decreased fi brinolysis might promote the damage to blood vessels and subsequent fi brin deposition. The necessity of A ␤ to initiate the infl ammatory process is indicated by the low level of neuroinfl ammation in the plasminogen-defi cient mouse.
AD and the tPA/plasmin fi brinolytic system tPA/plasmin fi brinolytic activity is regulated by serine protease inhibitors (serpins), such as plasminogen activator inhibitor-1 (PAI-1). In mice, PAI-1 is up-regulated in the presence of A ␤ , which agrees with the clinically observed elevation of PAI-1 levels in the cerebrospinal fl uid of AD patients ( 11, 27, 32 ) and decreased plasmin activity in the AD brain ( 10 ) .
The tPA/plasmin system is down-regulated in AD, in accord with reductions in other naturally occurring A ␤ -degrading proteases ( 10, 33, 34 ) . The direct consequences of this general lack of protease activity might be the diminished clearance of A ␤ peptide ( 34 ) . The present study proposes that decreases in clearance of fi brin can also contribute to the progression of A ␤ pathology.
It is important to consider the eff ects of the loss of a single copy of the plasminogen gene. Heterozygosity decreases the fi brinolytic activity to 55% of normal in pooled plasma obtained from wild-type mice according to clot lysis assays ( 35 ) . We did not attempt to generate TgCRND8;plg Ϫ/Ϫ mice because plg Ϫ/Ϫ mice develop several thrombotic complications, which could complicate the central nervous system pathology. Carl Zeiss MicroImaging, Inc.). Optical slices were processed by AxioVision confocal imaging software, and reconstructed images were evaluated for Evans blue dye present outside the fl uorescein-delineated intraluminal space. For views of the entire brain hemisphere, a composite of stitched 10ϫ images (8 ϫ 8) was produced during acquisition with a motorized stage.
ELISA (brain or plasma).
Brains were perfused, weighed, and homogenized in 0.1 M Tris, pH 7.2/0.2% Triton X-100 with 5 mM EDTA, 100 mM tranexamic acid, and protease inhibitor cocktail (Roche). Protein concentrations were measured by Lowry Assay (Bio-Rad Laboratories, Inc.). Quantifi cation of fi brinogen was performed using a hamster anti -mouse fi brinogen-capturing antibody, 7E9, provided by M. Jirouskova (The Rockefeller University, New York, NY; reference 47 ) and HRP-conjugated rabbit anti -human fi brinogendetecting antibody (DakoCytomation). A ␤ levels were measured by ELISA according to the manufacturer ' s protocol (Biosource International).
Immunostaining and semiquantitative analysis. To localize the leakage of Evans blue dye, one brain hemisphere was sectioned and fi xed with ice-cold ethanol. To evaluate fi brinogen extravasation and deposition, sections from Evans blue dye -treated animals were processed for fi brinogen immunoreactivity with a FITC-conjugated anti-fi brinogen antibody (DakoCytomation). Microglial staining was performed with a biotin-conjugated anti-CD11b antibody (1:100; BD Biosciences) visualized with FITC-or Rhodamine-conjugated avidin (1:500). To analyze microvasculature, rat anti -PECAM-1 antibody (BD Biosciences) was used (1:50) and visualized with an FITC-conjugated goat anti -rat antibody (1:1,000). A ␤ was detected with a rabbit anti -pan-A ␤ antibody (1:100; Biosource International). Apoptotic cells were stained with a rabbit anti -active caspase-3 antibody (1:200; Cell Signaling Technology, Inc.).
Coronal sections (from bregma − 1.5 to − 2.0 mm) were processed and stained for the markers listed above. A composite (3 ϫ 3) of 10ϫ images was stitched together to include hippocampus and cortex during acquisition using a laser-scanning confocal imaging system equipped with a motorized stage (LSM 510 confocal system fi tted on an Axiovert 200 inverted microscope). Composite images were converted 1-bit images using ImageJ (http:// rsb.info.nih.gov/ij/). Using this bit depth, regions including hippocampus, cortex, or both were selected by hand as shown in Figs. 3 and 4 and quantifi ed for percentage of immunofl uorescence.
Fluoro-Jade B staining. Fluoro-Jade B staining was performed according to the protocol by Schmued and Hopkins ( 54 ) and viewed under fl uorescence microscopy. In brief, sections were immersed sequentially in 1% NaOH/80% alcohol for 2 min, 70% alcohol for 2 min, water for 2 min, 0.06% potassium permanganate for 10 min, water for 2 min, and 0.0004% Fluoro-Jade B in 1% acetic acid for 20 min, and then rinsed in water three times. The sections were then dried, immersed in Histoclear, and mounted with neutral DPX polystyrene medium. The sections were viewed under blue-green excitation light with a fl uorescent microscope.
Ancrod/tranexamic acid treatments. To explore whether removal of fi brinogen from the circulation can aff ect the progression of A ␤ pathology, we treated transgenic mice with Viprinex (ancrod; provided by D.E. Levy, Neurobiological Technologies, Inc., Emeryville, CA). Mini-osmotic pumps were subcutaneously implanted to deliver 4 U/day of ancrod activity over 4 wk with replacement at 2 wk while a control group received saline (DURECT Corp.). To measure the fi brinogen-depletion eff ect of ancrod, plasma samples were obtained weekly by tail prick, and fi brinogen was quantifi ed by ELISA.
Defi ciency in fi brinolysis was accomplished pharmacologically by implantation of a mini-osmotic pump for delivery of tranexamic acid. Because the drug is also orally active, this dosage was supplemented with tranexamic acid dissolved in drinking water at 20 mg/ml. The total daily dose was estimated to be 100 mg/day. Online supplemental material. Fig. S1 shows examples of neurovascular staining in untreated 6-mo NTg and TgCRND8 mice. Fig. S2 shows PDAPP;plg +/Ϫ mice compared with PDAPP littermates, and references the all forms of fi brinogen. Similarly, Triton X-100 -soluble A ␤ levels likely underestimate the total A ␤ burden. However, A ␤ levels measured by ELISA correlate with plaque burdens observed with immunofl uorescence. Both soluble and insoluble fi brin activates microglia via the CD11b receptor and contributes to the observed infl ammation in A ␤ PP transgenic mice and AD patients.
This study begins to outline a role for fi brin in the neuroinfl ammation seen in AD. These results also indicate a role for fi brin deposition in accelerating the neurovascular damage observed in these mouse models and perhaps in reducing the brain ' s reparative capacity. Extravascular fi brinogen functioning as a restraint to mechanisms of tissue repair has been shown in the peripheral nervous system ( 48 ) . The present study also demonstrates this eff ect on the progression of disease in mouse models of AD. Therefore, fi brin and the mechanisms involved in its clearance may present novel therapeutic targets in slowing the progression of AD.
MATERIALS AND METHODS

Animals.
The AD transgenic mice used, which develop A ␤ -associated pathology, include Tg2576 ( 49 ), TgCRND8 ( 50 ) , and PDAPP ( 51 ) . The Tg2576 mice (APP695; K670N and M671L driven by the human prion protein promoter) are on a C57B6/SJL mixed strain background and develop cognitive deficits by 9 mo of age. The TgCRND8 mice (APP695; K670N, M671L, and V717F driven by the human prion protein promoter) are on a mixed background (C57XC3H/C57) and exhibit defects in memory as early as 3 mo of age (provided by A. Chishti and D. Westaway, University of Toronto, Toronto, Canada). The PDAPP mice (APP695, -751, and -770; V717F driven by the plateletderived growth factor ␤ promoter) used in this study were backcrossed to C57BL/6 mice and display memory defects by 8 mo (provided by R.B. Demattos and S.M. Paul, Eli Lilly Research Laboratories, Indianapolis, IN). Mice deficient for plasminogen ( 7 ) and fibrinogen ( 36, 52 ), both backcrossed onto the C57BL/6 background, were used for crosses with TgCRND8 and PDAPP mice. Littermates were used in all experiments whenever transgenic mice were compared with nontransgenic (wild-type) mice. Where multiple crosses or strains are presented in a single figure, nontransgenic littermates from each cross were averaged and presented as one bar for clarity and brevity. Mice were maintained in the Rockefeller University Laboratory Animal Research Center (LARC) and treated in accordance with protocols approved by LARC.
Evans blue extravasation assay. A solution of 2% Evans blue/PBS was injected (4 ml/kg) via the tail vein. 6 h after injection, the mice were anesthetized and blood was drawn by cardiac puncture followed by transcardial perfusion with 0.9% saline-heparin (5 U/ml) to remove intravascular dye. One brain hemisphere was frozen for sectioning and microscopy studies, whereas the other hemisphere was weighed and homogenized in 400 l dimethylformamide to solubilize the Evans blue. To extract the dye, samples were centrifuged, and the supernatant was collected and analyzed for absorbance at 620 nm. The plasma was diluted 1:100 in dimethylformamide and analyzed exactly as the brain homogenate. Evans blue units of extravasation were calculated as the A 620 of brain homogenate divided by the A 620 of plasma.
Evans blue fl uorescence profi ling. To visualize the extent of the bloodbrain barrier damage, mice were injected via tail vein with Evans blue dye. After 6 h, mice were anesthetized and perfused with a solution containing large-fragment 2,000-kD FITC-conjugated dextran dissolved in PBS to outline the intraluminal space ( 53 ) . Evans blue fl uorescence from 50-m coronal sections was visualized with a laser-scanning confocal imaging system (LSM 510 confocal system fi tted on an Axiovert 200 inverted microscope;
